Atiprosin, a chemically novel octahydro-pyrazino-pyrido-indole, exerts antihypertensive effects in spontaneously hypertensive, deoxycorticosterone acetate hypertensive, and renal-hypertensive rats over a dose range of 0.1-10 mg/kg per os (p.o.). In terms of relative potency, atiprosin was calculated to be seven to fifteen times less potent than prazosin, five to sixteen times more potent than ketanserin, and 14-25 times more potent than indoramin, depending on the hypertensive model examined. Atiprosin had good oral bioavailability (p.o./i.v. ratio = 1.25), and there was no evidence from rat studies for tolerance on repeated administration. The compound also exerted hypotensive effects in normotensive rats and monkeys at 1-10 mg/kg p.o.; in neither species was there evidence of drug-induced tachycardia. Experiments in anesthetized dogs suggest that atiprosin may be similar to prazosin with respect to its liability to produce orthostatic hypotension as a side effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005344-198709000-00014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thirteen serum biochemical indexes and five whole blood coagulation indices in a point-of-care testing analyzer: ideal protocol for evaluating pulmonary and critical care medicine.
J Zhejiang Univ Sci B
January 2025
Department of Clinical Laboratory, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Laboratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510140, China.
The accurate and timely detection of biochemical coagulation indicators is pivotal in pulmonary and critical care medicine. Despite their reliability, traditional laboratories often lag in terms of rapid diagnosis. Point-of-care testing (POCT) has emerged as a promising alternative, which is awaiting rigorous validation.
View Article and Find Full Text PDFAcridine/Lewis Acid Complexes as Powerful Photocatalysts: A Combined Experimental and Mechanistic Study.
ACS Catal
October 2024
Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, Florida 32611, United States.
A class of generated Lewis acid (LA) activated acridine complexes is reported, which act as potent photochemical catalysts for the oxidation of a variety of protected secondary amines. Acridine/LA complexes exhibit tunable excited state reduction potentials ranging from +2.07 to 2.
View Article and Find Full Text PDFArtificial Intelligence in Computer-Aided Drug Design (CADD) Tools for the Finding of Potent Biologically Active Small Molecules: Traditional to Modern Approach.
Comb Chem High Throughput Screen
January 2025
Department of Chemistry, Integral University, Lucknow, India.
Computer-Aided Drug Design (CADD) entails designing molecules that could potentially interact with a specific biomolecular target and promising their potential binding. The stereo- arrangement and stereo-selectivity of small molecules (SMs)--based chemotherapeutic agents significantly influence their therapeutic potential and enhance their therapeutic advantages. CADD has been a well-established field for decades, but recent years have observed a significant shift toward acceptance of computational approaches in both academia and the pharmaceutical industry.
View Article and Find Full Text PDFDevelopment of multifunctional fluorescence-emitting potential theranostic agents for Alzheimer's disease.
Talanta
January 2025
Pharmaceutical Chemistry Research Laboratory I, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India. Electronic address:
The cholinergic deficits and amyloid beta (Aβ) aggregation are the mainstream simultaneously observed pathologies during the progression of Alzheimer's disease (AD). Deposited Aβ plaques are considered to be the primary pathological hallmarks of AD and are contemplated as promising diagnostic biomarker. Herein, a series of novel theranostic agents were designed, synthesised and evaluated against cholinesterase (ChEs) enzymes and detection of Aβ species, which are major targets for development of therapeutics for AD.
View Article and Find Full Text PDFDiscovery of CZY43 as a new small-molecule degrader of pseudokinase HER3.
Eur J Med Chem
January 2025
State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd, Shanghai, 200032, China. Electronic address:
The pseudokinase HER3 emerges as a promising anti-cancer target, especially for HER2-driven breast cancer and EGFR-mediated non-small cell lung cancer. However, it is challenging to target HER3 by ATP-competitive small molecules because HER3 is catalytically impaired. Herein, we report the discovery of a series of HER3 degraders by connecting a HER3 binder bosutinib with a hydrophobic tag adamantane.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!